Top

Published in:

01-06-2009 | Review

Obstructive sleep apnea, immuno-inflammation, and atherosclerosis

Authors: Claire Arnaud, Maurice Dematteis, Jean-Louis Pepin, Jean-Philippe Baguet, Patrick Lévy

Published in: Seminars in Immunopathology | Issue 1/2009

Abstract

Obstructive sleep apnea (OSA) is a highly prevalent sleep disorder leading to cardiovascular and metabolic complications. OSA is also a multicomponent disorder, with intermittent hypoxia (IH) as the main trigger for the associated cardiovascular and metabolic alterations. Indeed, recurrent pharyngeal collapses during sleep lead to repetitive sequences of hypoxia–reoxygenation. This IH induces several consequences such as hemodynamic, hormonometabolic, oxidative, and immuno-inflammatory alterations that may interact and aggravate each other, resulting in artery changes, from adaptive to degenerative atherosclerotic remodeling. Atherosclerosis has been found in OSA patients free of other cardiovascular risk factors and is related to the severity of nocturnal hypoxia. Early stages of artery alteration, including functional and structural changes, have been evidenced in both OSA patients and rodents experimentally exposed to IH. Impaired vasoreactivity with endothelial dysfunction and/or increased vasoconstrictive responses due to sympathetic, endothelin, and renin–angiotensin systems have been reported and also contribute to vascular remodeling and inflammation. Oxidative stress, inflammation, and vascular remodeling can be directly triggered by IH, further aggravated by the OSA-associated hormonometabolic alterations, such as insulin resistance, dyslipidemia, and adipokine imbalance. As shown in OSA patients and in the animal model, genetic susceptibility, comorbidities (obesity), and life habits (high fat diet) may aggravate atherosclerosis development or progression. The intimate molecular mechanisms are still largely unknown, and their understanding may contribute to delineate new targets for prevention strategies and/or development of new treatment of OSA-related atherosclerosis, especially in patients at risk for cardiovascular disease.

Malhotra A, White DP (2002) Obstructive sleep apnoea. Lancet 360(9328):237–245. doi:10.1016/S0140-6736(02) 09464-3 PubMedCrossRef

Somers VK et al (2008) Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 118(10):1080–1111. doi:10.1161/CIRCULATIONAHA.107.189420 PubMedCrossRef

Mayer P et al (1996) Relationship between body mass index, age and upper airway measurements in snorers and sleep apnoea patients. Eur Respir J 9(9):1801–1809. doi:10.1183/09031936.96.09091801 PubMedCrossRef

White DP (2005) Pathogenesis of obstructive and central sleep apnea. Am J Respir Crit Care Med 172(11):1363–1370. doi:10.1164/rccm.200412-1631SO PubMedCrossRef

Horner RL (2007) Contributions of passive mechanical loads and active neuromuscular compensation to upper airway collapsibility during sleep. J Appl Physiol 102(2):510–512. doi:10.1152/japplphysiol.01213.2006 PubMedCrossRef

Levy P et al (2008) Intermittent hypoxia and sleep-disordered breathing: current concepts and perspectives. Eur Respir J 32(4):1082–1095. doi:10.1183/09031936.00013308 PubMedCrossRef

Young T et al (1993) The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328(17):1230–1235. doi:10.1056/NEJM199304293281704 PubMedCrossRef

Young T, Peppard PE, Gottlieb DJ (2002) Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 165(9):1217–1239. doi:10.1164/rccm.2109080 PubMedCrossRef

Teran-Santos J, Jimenez-Gomez A, Cordero-Guevara J (1999) The association between sleep apnea and the risk of traffic accidents. Cooperative Group Burgos-Santander. N Engl J Med 340(11):847–851. doi:10.1056/NEJM199903183401104 PubMedCrossRef

10.

Mazza S et al (2002) Analysis of error profiles occurring during the OSLER test: a sensitive mean of detecting fluctuations in vigilance in patients with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 166(4):474–478. doi:10.1164/rccm.2107065 PubMedCrossRef

11.

Marin JM et al (2005) Long-term cardiovascular outcomes in men with obstructive sleep apnoea–hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 365(9464):1046–1053PubMed

12.

Pepperell JC et al (2002) Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 359(9302):204–210. doi:10.1016/S0140-6736(02)07445-7 PubMedCrossRef

13.

Yaggi HK et al (2005) Obstructive sleep apnea as a risk factor for stroke and death. N Engl J Med 353(19):2034–2041. doi:10.1056/NEJMoa043104 PubMedCrossRef

14.

Somers VK et al (2008) Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. J Am Coll Cardiol 52(8):686–717. doi:10.1016/j.jacc.2008.05.002 PubMedCrossRef

15.

Young T et al (2008) Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep 31(8):1071–1078PubMed

16.

Baguet JP et al (2005) The severity of oxygen desaturation is predictive of carotid wall thickening and plaque occurrence. Chest 128(5):3407–3412. doi:10.1378/chest.128.5.3407 PubMedCrossRef

17.

Minoguchi K et al (2005) Increased carotid intima–media thickness and serum inflammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med 172(5):625–630. doi:10.1164/rccm.200412-1652OC PubMedCrossRef

18.

Drager LF et al (2005) Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 172(5):613–618. doi:10.1164/rccm.200503-340OC PubMedCrossRef

19.

Turmel J et al (2009) Relationship between atherosclerosis and the sleep apnea syndrome: an intravascular ultrasound study. Int J Cardiol 132(2):203–209. doi:10.1016/j.ijcard.2007.11.063 PubMedCrossRef

20.

Basner RC (2007) Continuous positive airway pressure for obstructive sleep apnea. N Engl J Med 356(17):1751–1758. doi:10.1056/NEJMct066953 PubMedCrossRef

21.

Jenkinson C et al (1999) Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial. Lancet 353(9170):2100–2105. doi:10.1016/S0140-6736(98)10532-9 PubMedCrossRef

22.

Montserrat JM et al (2001) Effectiveness of CPAP treatment in daytime function in sleep apnea syndrome. A randomized controlled study with an optimized placebo. Am J Respir Crit Care Med 164(4):608–613PubMed

23.

Haentjens P et al (2007) The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-controlled randomized trials. Arch Intern Med 167(8):757–764. doi:10.1001/archinte.167.8.757 PubMedCrossRef

24.

Lévy P et al (2009) Obstructive sleep apnea and atherosclerosis. Prog Cardiovasc Dis 51(5):400–410. doi:10.1016/j.pcad.2008.03.001 PubMedCrossRef

25.

Gay P et al (2006) Evaluation of positive airway pressure treatment for sleep related breathing disorders in adults. Sleep 29(3):381–401PubMed

26.

Pepin JL et al (1999) Effective compliance during the first 3 months of continuous positive airway pressure. A European prospective study of 121 patients. Am J Respir Crit Care Med 160(4):1124–1129PubMed

27.

Weaver TE et al (2007) Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. Sleep 30(6):711–719PubMed

28.

Harsch IA et al (2004) Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 169(2):156–162. doi:10.1164/rccm.200302-206OC PubMedCrossRef

29.

Coughlin SR et al (2007) Cardiovascular and metabolic effects of CPAP in obese males with OSA. Eur Respir J 29(4):720–727. doi:10.1183/09031936.00043306 PubMedCrossRef

30.

West SD et al (2007) Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax 62(11):969–974. doi:10.1136/thx.2006.074351 PubMedCrossRef

31.

Dematteis M et al. (2009) Cardiovascular consequences of sleep disordered breathing: contribution of animal models to understanding the human disease. ILAR J 50(3)

32.

Kimoff RJ et al (1994) Canine model of obstructive sleep apnea: model description and preliminary application. J Appl Physiol 76(4):1810–1817PubMed

33.

Brooks D et al (1997) Obstructive sleep apnea as a cause of systemic hypertension. Evidence from a canine model. J Clin Invest 99(1):106–109. doi:10.1172/JCI119120 PubMedCrossRef

34.

Nacher M et al (2007) Recurrent obstructive apneas trigger early systemic inflammation in a rat model of sleep apnea. Respir Physiol Neurobiol 155(1):93–96. doi:10.1016/j.resp. 2006.06.004 PubMedCrossRef

35.

Neubauer JA (2001) Invited review: physiological and pathophysiological responses to intermittent hypoxia. J Appl Physiol 90(4):1593–1599PubMed

36.

Fletcher EC (2001) Invited review: physiological consequences of intermittent hypoxia: systemic blood pressure. J Appl Physiol 90(4):1600–1605PubMed

37.

Morgan BJ (2007) Vascular consequences of intermittent hypoxia. Adv Exp Med Biol 618:69–84. doi:10.1007/978-0-387-75434-5_6 PubMedCrossRef

38.

Prabhakar NR (2001) Oxygen sensing during intermittent hypoxia: cellular and molecular mechanisms. J Appl Physiol 90(5):1986–1994PubMed

39.

Dyugovskaya L, Lavie P, Lavie L (2002) Increased adhesion molecules expression and production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 165(7):934–939PubMed

40.

Ryan S, Taylor CT, McNicholas WT (2005) Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 112(17):2660–2667. doi:10.1161/CIRCULATIONAHA.105.556746 PubMedCrossRef

41.

Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352(16):1685–1695. doi:10.1056/NEJMra043430 PubMedCrossRef

42.

Libby P (2002) Inflammation in atherosclerosis. Nature 420(6917):868–874. doi:10.1038/nature01323 PubMedCrossRef

43.

Lusis AJ (2000) Atherosclerosis. Nature 407(6801):233–241. doi:10.1038/35025203 PubMedCrossRef

44.

Peppard PE et al (2000) Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 342(19):1378–1384. doi:10.1056/NEJM200005113421901 PubMedCrossRef

45.

Brooks D et al (1997) Effect of obstructive sleep apnea versus sleep fragmentation on responses to airway occlusion. Am J Respir Crit Care Med 155(5):1609–1617PubMed

46.

Smith ML, Pacchia CF (2007) Sleep apnoea and hypertension: role of chemoreflexes in humans. Exp Physiol 92(1):45–50. doi:10.1113/expphysiol.2006.033753 PubMedCrossRef

47.

Somers VK et al (1995) Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 96(4):1897–1904. doi:10.1172/JCI118235 PubMedCrossRef

48.

Dematteis M et al (2008) Intermittent hypoxia induces early functional cardiovascular remodeling in mice. Am J Respir Crit Care Med 177(2):227–235. doi:10.1164/rccm.200702-238OC PubMedCrossRef

49.

Chatzizisis YS et al (2007) Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol 49(25):2379–2393. doi:10.1016/j.jacc.2007.02.059 PubMedCrossRef

50.

Kato M et al (2000) Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation 102(21):2607–2610PubMed

51.

Kraiczi H et al (2001) Impairment of vascular endothelial function and left ventricular filling: association with the severity of apnea-induced hypoxemia during sleep. Chest 119(4):1085–1091. doi:10.1378/chest.119.4.1085 PubMedCrossRef

52.

Imadojemu VA et al (2002) Impaired vasodilator responses in obstructive sleep apnea are improved with continuous positive airway pressure therapy. Am J Respir Crit Care Med 165(7):950–953PubMed

53.

Imadojemu VA et al (2002) Obstructive apnea during sleep is associated with peripheral vasoconstriction. Am J Respir Crit Care Med 165(1):61–66PubMed

54.

Tahawi Z et al (2001) Altered vascular reactivity in arterioles of chronic intermittent hypoxic rats. J Appl Physiol 90(5):2007–2013 discussion 2000PubMed

55.

Phillips SA et al (2004) Chronic intermittent hypoxia impairs endothelium-dependent dilation in rat cerebral and skeletal muscle resistance arteries. Am J Physiol Heart Circ Physiol 286(1):H388–H393. doi:10.1152/ajpheart.00683.2003 PubMedCrossRef

56.

Lefebvre B et al (2006) Functional assessment of vascular reactivity after chronic intermittent hypoxia in the rat. Respir Physiol Neurobiol 150(2–3):278–286. doi:10.1016/j.resp. 2005.05.020 PubMedCrossRef

57.

Ip MS et al (2000) Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. Am J Respir Crit Care Med 162(6):2166–2171PubMed

58.

Lavie L et al (2003) Plasma levels of nitric oxide and L-arginine in sleep apnea patients: effects of nCPAP treatment. J Mol Neurosci 21(1):57–63. doi:10.1385/JMN:21:1:57 PubMedCrossRef

59.

Teramoto S et al (2003) Oxygen administration improves the serum level of nitric oxide metabolites in patients with obstructive sleep apnea syndrome. Sleep Med 4(5):403–407. doi:10.1016/S1389-9457(03)00102-3 PubMedCrossRef

60.

Ohike Y et al (2005) Amelioration of vascular endothelial dysfunction in obstructive sleep apnea syndrome by nasal continuous positive airway pressure—possible involvement of nitric oxide and asymmetric NG, NG-dimethylarginine. Circ J 69(2):221–226. doi:10.1253/circj.69.221 PubMedCrossRef

61.

Duchna HW et al (2005) Long-term effects of nasal continuous positive airway pressure on vasodilatory endothelial function in obstructive sleep apnea syndrome. Sleep Breath 9(3):97–103. doi:10.1007/s11325-005-0024-z PubMedCrossRef

62.

Lattimore JL et al (2006) Treatment of obstructive sleep apnoea leads to improved microvascular endothelial function in the systemic circulation. Thorax 61(6):491–495. doi:10.1136/thx.2004.039164 PubMedCrossRef

63.

Noda A et al (2007) Continuous positive airway pressure improves daytime baroreflex sensitivity and nitric oxide production in patients with moderate to severe obstructive sleep apnea syndrome. Hypertens Res 30(8):669–676. doi:10.1291/hypres.30.669 PubMedCrossRef

64.

Ozkan Y et al (2008) Circulating nitric oxide (NO), asymmetric dimethylarginine (ADMA), homocysteine, and oxidative status in obstructive sleep apnea–hypopnea syndrome (OSAHS). Sleep Breath 12(2):149–154. doi:10.1007/s11325-007-0148-4 PubMedCrossRef

65.

Mason RP (2006) Nitric oxide mechanisms in the pathogenesis of global risk. J Clin Hypertens (Greenwich) 8(8 Suppl 2):31–38. doi:10.1111/j.1524-6175.2006.05838.x quiz 40CrossRef

66.

Belaidi E et al (2009) Major role for HIF-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea. J Am Coll Cardiol 53(15):1309–1317PubMedCrossRef

67.

Mulvany MJ et al (1996) Vascular remodeling. Hypertension 28(3):505–506PubMed

68.

Drager LF et al (2007) Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 176(7):706–712. doi:10.1164/rccm.200703-500OC PubMedCrossRef

69.

Arnaud C et al. (2008) Intermittent hypoxia induces inflammatory vascular remodeling in C57bl6 mice. In: American Thoracic Society 2008 International Conference. Am J Resp Crit Care Med 177, Meeting abstracts, 2008, Toronto, Canada

70.

Belaidi E et al. (2008) Dual endothelin-1 receptor antagonism prevents chronic intermittent hypoxia-induced cardiovascular alterations in rat. In: European Respiratory Society 2008 International Conference. Eur Resp J 32(suppl 52), Meeting abstract, 2008, Berlin, Germany

71.

Arnaud C et al. (2009) Intermittent hypoxia induces inflammatory vascular and myocardial remodeling: role of the endothelin system. In: American Thoracic Society 2009 International Conference. Am J Respir Crit Care Med 179, Meeting Abstracts, 2009, San Diego, USA

72.

Allahdadi KJ, Walker BR, Kanagy NL (2005) Augmented endothelin vasoconstriction in intermittent hypoxia-induced hypertension. Hypertension 45(4):705–709. doi:10.1161/01.HYP.0000153794.52852.04 PubMedCrossRef

73.

Lefebvre B et al (2008) Leukotriene B4: early mediator of atherosclerosis in obstructive sleep apnoea? Eur Respir J 32(1):113–120. doi:10.1183/09031936.00137107 PubMedCrossRef

74.

Chapman MJ, Sposito AC (2008) Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy. Pharmacol Ther 117(3):354–373. doi:10.1016/j.pharmthera.2007.10.004 PubMedCrossRef

75.

Newman AB et al (2005) Progression and regression of sleep-disordered breathing with changes in weight: the sleep heart health study. Arch Intern Med 165(20):2408–2413. doi:10.1001/archinte.165.20.2408 PubMedCrossRef

76.

Peled N et al (2007) The association of OSA with insulin resistance, inflammation and metabolic syndrome. Respir Med 101(8):1696–1701. doi:10.1016/j.rmed.2007.02.025 PubMedCrossRef

77.

Kono M et al (2007) Obstructive sleep apnea syndrome is associated with some components of metabolic syndrome. Chest 131(5):1387–1392. doi:10.1378/chest.06-1807 PubMedCrossRef

78.

Meslier N et al (2003) Impaired glucose-insulin metabolism in males with obstructive sleep apnoea syndrome. Eur Respir J 22(1):156–160. doi:10.1183/09031936.03.00089902 PubMedCrossRef

79.

Strohl KP et al (1994) Insulin levels, blood pressure and sleep apnea. Sleep 17(7):614–618PubMed

80.

Vgontzas AN et al (2000) Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 85(3):1151–1158. doi:10.1210/jc.85.3.1151 PubMedCrossRef

81.

Ip MS et al (2002) Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 165(5):670–676PubMed

82.

McArdle N et al (2007) Metabolic risk factors for vascular disease in obstructive sleep apnea: a matched controlled study. Am J Respir Crit Care Med 175(2):190–195. doi:10.1164/rccm.200602-270OC PubMedCrossRef

83.

Punjabi NM et al (2002) Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. Am J Respir Crit Care Med 165(5):677–682PubMed

84.

Stoohs RA, Facchini F, Guilleminault C (1996) Insulin resistance and sleep-disordered breathing in healthy humans. Am J Respir Crit Care Med 154(1):170–174PubMed

85.

Sharma SK et al (2007) Obesity, and not obstructive sleep apnea, is responsible for metabolic abnormalities in a cohort with sleep-disordered breathing. Sleep Med 8(1):12–17. doi:10.1016/j.sleep. 2006.06.014 PubMedCrossRef

86.

Barcelo A et al (2008) Insulin resistance and daytime sleepiness in patients with sleep apnoea. Thorax 63(11):946–950. doi:10.1136/thx.2007.093740 PubMedCrossRef

87.

Polotsky VY et al (2009) Obstructive sleep apnea, insulin resistance, and steatohepatitis in severe obesity. Am J Respir Crit Care Med 179(3):228–234. doi:10.1164/rccm.200804-608OC PubMedCrossRef

88.

Muniyappa R et al (2007) Cardiovascular actions of insulin. Endocr Rev 28(5):463–491. doi:10.1210/er.2007-0006 PubMedCrossRef

89.

Nigro J et al (2006) Insulin resistance and atherosclerosis. Endocr Rev 27(3):242–259. doi:10.1210/er.2005-0007 PubMedCrossRef

90.

Polotsky VY et al (2003) Intermittent hypoxia increases insulin resistance in genetically obese mice. J Physiol 552(Pt 1):253–264. doi:10.1113/jphysiol.2003.048173 PubMedCrossRef

91.

Martin SS, Qasim A, Reilly MP (2008) Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol 52(15):1201–1210. doi:10.1016/j.jacc.2008.05.060 PubMedCrossRef

92.

Dubey L, Hesong Z (2006) Role of leptin in atherogenesis. Exp Clin Cardiol 11(4):269–275PubMed

93.

Beltowski J (2006) Leptin and atherosclerosis. Atherosclerosis 189(1):47–60. doi:10.1016/j.atherosclerosis.2006.03.003 PubMedCrossRef

94.

Sierra-Johnson J et al (2008) Effect of altitude on leptin levels, does it go up or down? J Appl Physiol 105(5):1684–1685. doi:10.1152/japplphysiol.01284.2007 PubMedCrossRef

95.

Grosfeld A et al (2002) Hypoxia-inducible factor 1 transactivates the human leptin gene promoter. J Biol Chem 277(45):42953–42957. doi:10.1074/jbc.M206775200 PubMedCrossRef

96.

Barcelo A et al (2005) Neuropeptide Y and leptin in patients with obstructive sleep apnea syndrome: role of obesity. Am J Respir Crit Care Med 171(2):183–187. doi:10.1164/rccm.200405-579OC PubMedCrossRef

97.

Borgel J et al (2006) Obstructive sleep apnoea and its therapy influence high-density lipoprotein cholesterol serum levels. Eur Respir J 27(1):121–127. doi:10.1183/09031936.06.00131304 PubMedCrossRef

98.

Saarelainen S, Lahtela J, Kallonen E (1997) Effect of nasal CPAP treatment on insulin sensitivity and plasma leptin. J Sleep Res 6(2):146–147PubMed

99.

Chin K et al (1999) Changes in intra-abdominal visceral fat and serum leptin levels in patients with obstructive sleep apnea syndrome following nasal continuous positive airway pressure therapy. Circulation 100(7):706–712PubMed

100.

Ip MS et al (2000) Serum leptin and vascular risk factors in obstructive sleep apnea. Chest 118(3):580–586. doi:10.1378/chest.118.3.580 PubMedCrossRef

101.

Shimizu K et al (2002) Plasma leptin levels and cardiac sympathetic function in patients with obstructive sleep apnoea–hypopnoea syndrome. Thorax 57(5):429–434. doi:10.1136/thorax.57.5.429 PubMedCrossRef

102.

Okamoto Y et al (2006) Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 110(3):267–278. doi:10.1042/CS20050182 CrossRef

103.

Gualillo O, Gonzalez-Juanatey JR, Lago F (2007) The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med 17(8):275–283. doi:10.1016/j.tcm.2007.09.005 PubMedCrossRef

104.

Lago F et al (2007) Adipokines as emerging mediators of immune response and inflammation. Nat Clin Pract Rheumatol 3(12):716–724. doi:10.1038/ncprheum0674 PubMedCrossRef

105.

Makino S et al (2006) Obstructive sleep apnoea syndrome, plasma adiponectin levels, and insulin resistance. Clin Endocrinol (Oxf) 64(1):12–19. doi:10.1111/j.1365-2265.2005.02407.x CrossRef

106.

Tokuda F et al (2008) Serum levels of adipocytokines, adiponectin and leptin, in patients with obstructive sleep apnea syndrome. Intern Med 47(21):1843–1849. doi:10.2169/internalmedicine.47.1035 PubMedCrossRef

107.

Wolk R et al (2005) Plasma levels of adiponectin, a novel adipocyte-derived hormone, in sleep apnea. Obes Res 13(1):186–190. doi:10.1038/oby.2005.24 PubMedCrossRef

108.

Zhang XL et al (2004) Serum adiponectin level in patients with obstructive sleep apnea hypopnea syndrome. Chin Med J (Engl) 117(11):1603–1606

109.

Zhang XL et al (2006) Serum adiponectin levels in adult male patients with obstructive sleep apnea hypopnea syndrome. Respiration 73(1):73–77. doi:10.1159/000088690 PubMedCrossRef

110.

Masserini B et al (2006) Reduced levels of adiponectin in sleep apnea syndrome. J Endocrinol Invest 29(8):700–705PubMed

111.

Zhang XL et al (2007) Effect of continuous positive airway pressure treatment on serum adiponectin level and mean arterial pressure in male patients with obstructive sleep apnea syndrome. Chin Med J (Engl) 120(17):1477–1481

112.

Nakagawa Y et al (2008) Nocturnal reduction in circulating adiponectin concentrations related to hypoxic stress in severe obstructive sleep apnea–hypopnea syndrome. Am J Physiol Endocrinol Metab 294(4):E778–E784. doi:10.1152/ajpendo.00709.2007 PubMedCrossRef

113.

Kanbay A et al (2008) Comparison of serum adiponectin and tumor necrosis factor-alpha levels between patients with and without obstructive sleep apnea syndrome. Respiration 76(3):324–330. doi:10.1159/000134010 PubMedCrossRef

114.

Lam JC et al (2008) Hypoadiponectinemia is related to sympathetic activation and severity of obstructive sleep apnea. Sleep 31(12):1721–1727PubMed

115.

Chen B et al (2006) Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes. Biochem Biophys Res Commun 341(2):549–556. doi:10.1016/j.bbrc.2006.01.004 PubMedCrossRef

116.

Hosogai N et al (2007) Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 56(4):901–911. doi:10.2337/db06-0911 PubMedCrossRef

117.

Wang B, Wood IS, Trayhurn P (2007) Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes. Pflugers Arch 455(3):479–492. doi:10.1007/s00424-007-0301-8 PubMedCrossRef

118.

Ye J et al (2007) Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 293(4):E1118–E1128. doi:10.1152/ajpendo.00435.2007 PubMedCrossRef

119.

Magalang UJ et al (2008) Intermittent hypoxia suppresses adiponectin secretion by adipocytes. Exp Clin Endocrinol Diabetes 117:129–134PubMedCrossRef

120.

Yamamoto Y et al (2008) Resistin is closely related to systemic inflammation in obstructive sleep apnea. Respiration 76(4):377–385. doi:10.1159/000141866 PubMedCrossRef

121.

Wu H et al (2007) T-cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation 115(8):1029–1038. doi:10.1161/CIRCULATIONAHA.106.638379 PubMedCrossRef

122.

Thalmann S, Meier CA (2007) Local adipose tissue depots as cardiovascular risk factors. Cardiovasc Res 75(4):690–701. doi:10.1016/j.cardiores.2007.03.008 PubMedCrossRef

123.

Henrichot E et al (2005) Production of chemokines by perivascular adipose tissue: a role in the pathogenesis of atherosclerosis? Arterioscler Thromb Vasc Biol 25(12):2594–2599. doi:10.1161/01.ATV.0000188508.40052.35 PubMedCrossRef

124.

McGill HC Jr et al (2002) Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation 105(23):2712–2718. doi:10.1161/01.CIR.0000018121.67607.CE PubMedCrossRef

125.

Fantuzzi G, Mazzone T (2007) Adipose tissue and atherosclerosis: exploring the connection. Arterioscler Thromb Vasc Biol 27(5):996–1003. doi:10.1161/ATVBAHA.106.131755 PubMedCrossRef

126.

Ohman MK et al (2008) Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice. Circulation 117(6):798–805. doi:10.1161/CIRCULATIONAHA.107.717595 PubMedCrossRef

127.

Vela D et al (2007) The role of periadventitial fat in atherosclerosis. Arch Pathol Lab Med 131(3):481–487PubMed

128.

Newman AB et al (2001) Relation of sleep-disordered breathing to cardiovascular disease risk factors: the Sleep Heart Health Study. Am J Epidemiol 154(1):50–59. doi:10.1093/aje/154.1.50 PubMedCrossRef

129.

Robinson GV et al (2004) Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. Thorax 59(9):777–782. doi:10.1136/thx.2003.018739 PubMedCrossRef

130.

Lavie L (2003) Obstructive sleep apnoea syndrome—an oxidative stress disorder. Sleep Med Rev 7(1):35–51. doi:10.1053/smrv.2002.0261 PubMedCrossRef

131.

Tan KC et al (2005) HDL dysfunction in obstructive sleep apnea. Atherosclerosis 184:377–382PubMedCrossRef

132.

Lavie L, Vishnevsky A, Lavie P (2004) Evidence for lipid peroxidation in obstructive sleep apnea. Sleep 27(1):123–128PubMed

133.

Li J et al (2005) Intermittent hypoxia induces hyperlipidemia in lean mice. Circ Res 97(7):698–706. doi:10.1161/01.RES.0000183879.60089.a9 PubMedCrossRef

134.

Li J et al (2007) Hyperlipidemia and lipid peroxidation are dependent on the severity of chronic intermittent hypoxia. J Appl Physiol 102(2):557–563. doi:10.1152/japplphysiol.01081.2006 PubMedCrossRef

135.

Lattimore JD et al (2005) Repetitive hypoxia increases lipid loading in human macrophages—a potentially atherogenic effect. Atherosclerosis 179(2):255–259. doi:10.1016/j.atherosclerosis.2004.11.010 PubMedCrossRef

136.

Savransky V et al (2007) Chronic intermittent hypoxia induces atherosclerosis. Am J Respir Crit Care Med 175(12):1290–1297. doi:10.1164/rccm.200612-1771OC PubMedCrossRef

137.

Savransky V et al (2008) Dyslipidemia and atherosclerosis induced by chronic intermittent hypoxia are attenuated by deficiency of stearoyl coenzyme A desaturase. Circ Res 103(10):1173–1180. doi:10.1161/CIRCRESAHA.108.178533 PubMedCrossRef

138.

McNicholas WT, Bonsignore MR (2007) Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 29(1):156–178. doi:10.1183/09031936.00027406 PubMedCrossRef

139.

Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444(7121):860–867. doi:10.1038/nature05485 PubMedCrossRef

140.

Shamsuzzaman AS et al (2002) Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation 105(21):2462–2464. doi:10.1161/01.CIR.0000018948.95175.03 PubMedCrossRef

141.

Yokoe T et al (2003) Elevated levels of C-reactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 107(8):1129–1134. doi:10.1161/01.CIR.0000052627.99976.18 PubMedCrossRef

142.

Yao M et al (2006) The relationship between sleep-disordered breathing and high-sensitivity C-reactive protein in Japanese men. Sleep 29(5):661–665PubMed

143.

Taheri S et al (2007) Correlates of serum C-reactive protein (CRP)—no association with sleep duration or sleep disordered breathing. Sleep 30(8):991–996PubMed

144.

Guilleminault C, Kirisoglu C, Ohayon MM (2004) C-reactive protein and sleep-disordered breathing. Sleep 27(8):1507–1511PubMed

145.

Kohler M et al (2009) Effects of continuous positive airway pressure on systemic inflammation in patients with moderate to severe obstructive sleep apnoea: a randomised controlled trial. Thorax 64(1):67–73. doi:10.1136/thx.2008.097931 PubMedCrossRef

146.

Carpagnano GE et al (2002) Increased 8-isoprostane and interleukin-6 in breath condensate of obstructive sleep apnea patients. Chest 122(4):1162–1167. doi:10.1378/chest.122.4.1162 PubMedCrossRef

147.

Ohga E et al (1999) Increased levels of circulating ICAM-1, VCAM-1, and L-selectin in obstructive sleep apnea syndrome. J Appl Physiol 87(1):10–14PubMed

148.

Ohga E et al (2003) Effects of obstructive sleep apnea on circulating ICAM-1, IL-8, and MCP-1. J Appl Physiol 94(1):179–184PubMed

149.

Schulz R et al (2000) Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med 162(2 Pt 1):566–570PubMed

150.

Dyugovskaya L et al (2008) Delayed neutrophil apoptosis in patients with sleep apnea. Am J Respir Crit Care Med 177(5):544–554. doi:10.1164/rccm.200705-675OC PubMedCrossRef

151.

Dyugovskaya L et al (2005) Activated CD8+ T-lymphocytes in obstructive sleep apnoea. Eur Respir J 25(5):820–828. doi:10.1183/09031936.05.00103204 PubMedCrossRef

152.

Dyugovskaya L, Lavie P, Lavie L (2005) Lymphocyte activation as a possible measure of atherosclerotic risk in patients with sleep apnea. Ann N Y Acad Sci 1051:340–350. doi:10.1196/annals.1361.076 PubMedCrossRef

153.

van Buul JD, Hordijk PL (2004) Signaling in leukocyte transendothelial migration. Arterioscler Thromb Vasc Biol 24(5):824–833. doi:10.1161/01.ATV.0000122854.76267.5c PubMedCrossRef

154.

Tzima E et al (2005) A mechanosensory complex that mediates the endothelial cell response to fluid shear stress. Nature 437(7057):426–431. doi:10.1038/nature03952 PubMedCrossRef

155.

Greenberg H et al (2006) Chronic intermittent hypoxia activates nuclear factor-kappaB in cardiovascular tissues in vivo. Biochem Biophys Res Commun 343(2):591–596. doi:10.1016/j.bbrc.2006.03.015 PubMedCrossRef

156.

Minoguchi K et al (2004) Elevated production of tumor necrosis factor-alpha by monocytes in patients with obstructive sleep apnea syndrome. Chest 126(5):1473–1479. doi:10.1378/chest.126.5.1473 PubMedCrossRef

157.

Paigen B et al (1985) Variation in susceptibility to atherosclerosis among inbred strains of mice. Atherosclerosis 57(1):65–73. doi:10.1016/0021-9150(85)90138-8 PubMedCrossRef

158.

Stewart-Phillips JL, Lough J (1991) Pathology of atherosclerosis in cholesterol-fed, susceptible mice. Atherosclerosis 90(2–3):211–218. doi:10.1016/0021-9150(91)90117-L PubMedCrossRef

159.

Hofker MH, van Vlijmen BJ, Havekes LM (1998) Transgenic mouse models to study the role of APOE in hyperlipidemia and atherosclerosis. Atherosclerosis 137(1):1–11. doi:10.1016/S0021-9150(97)00266-9 PubMedCrossRef

160.

Jun JC et al. (2008) Intermittent hypoxia accelerates aortic atherosclerosis in ApoE deficient mice. In: American Thoracic Society 2008 International Conference. Am J Resp Crit Care Med 177, Meeting abstract, 2008, Toronto, Canada

161.

Arnaud C et al. (2008) Chronic intermittent hypoxia accelerates atherosclerotic plaque formation in ApoE knockout mice independently of cholesterol levels. In: European Respiratory Society 2008 International Conference. Eur Resp J 32(suppl 52), Meeting abstract, 2008, Berlin, Germany.

Title: Obstructive sleep apnea, immuno-inflammation, and atherosclerosis
Authors: Claire Arnaud
Maurice Dematteis
Jean-Louis Pepin
Jean-Philippe Baguet
Patrick Lévy
Publication date: 01-06-2009
Publisher: Springer-Verlag
Published in: Seminars in Immunopathology / Issue 1/2009
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI: https://doi.org/10.1007/s00281-009-0148-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Obstructive sleep apnea, immuno-inflammation, and atherosclerosis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Innate and adaptive immunity in atherosclerosis

The emerging role of the endocannabinoid system in cardiovascular disease

Update on statin-mediated anti-inflammatory activities in atherosclerosis

CRP and the risk of atherosclerotic events

Connexins participate in the initiation and progression of atherosclerosis

Atherosclerosis is an inflammatory disease

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page